

Principal investigator Paul Sondel, MD, PhD, professor and research director, Division of Hematology, Oncology, and Bone Marrow Transplant, and co-investigator Amy Erbe-Gurel, PhD, research assistant professor, received a two-year, $125,000 award from Band of Parents for their study, “INV724 Bispecific mAb Pharmacokinetic-Pharmacodnamic Modeling to Optimize in Vivo Anti-neuroblastoma Efficacy.” The study aims to improve a treatment regimen for high-risk neuroblastoma with less pain, better quality of life, more potent anti-tumor efficacy, and a greater fraction of patients with long-term, tumor-free survival. Their work will do this by developing this novel bispecific antibody that binds to and kills neuroblastoma cells but does not bind to nerves. Their work will allow them to determine how to best use this novel antibody to improve the outcome and quality of life for children with neuroblastoma as well as provide important information for improving the efficacy of other anti-cancer antibodies. The grant funding begins in January 2025 and runs through December 2026.